臨床バイオマーカーの世界市場レポート 2025年

臨床バイオマーカー市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.8％で528億米ドルに成長します。予測期間の成長は、コンパニオン診断の拡大、早期診断と疾病予防への注力、精密腫瘍学と神経変性疾患におけるアプリケーションの増加、感染症の増加などに起因すると考えられます。予測期間の主な動向には、AIを活用したバイオマーカー探索、機械学習統合、マルチオミクス統合、技術革新、主要企業の提携などが含まれます。

がんの有病率の上昇は、今後数年間の臨床バイオマーカー市場の成長を促進すると予想されます。がんは、異常な細胞の無秩序な増殖と分裂を特徴とする疾患群を指し、健康な組織に侵入して損傷を与える可能性があります。臨床バイオマーカーは、早期発見、リスク評価、発症リスクの高い個人のモニタリングを支援するため、がん予防に不可欠です。例えば、英国を拠点とするがん研究機関であるCancer Research UKは、2023年から2025年の間に新規の腎臓がん患者が約16,300人から約21,900人に増加し、2038年から2040年までに15％増加すると予測しています。したがって、がんの有病率の高さが臨床バイオマーカー市場の成長に拍車をかけています。

高齢化人口の増加が予想されることも、臨床バイオマーカー市場の成長に寄与すると考えられます。高齢化とは、時間の経過とともに社会における高齢者の割合が増加することを特徴とする人口動態の変化を意味します。世界の高齢化は、加齢に関連する疾患の有病率の上昇と関連しており、早期診断と疾患管理を強化するバイオマーカーが必要とされています。2022年10月現在、世界保健機関（WHO）は、2030年までに世界の6人に1人が60歳以上になると予測しています。この間、60歳以上の人口は2020年の10億人から14億人に増加すると予測されています。さらに、2050年には、60歳以上の世界人口は倍増し、21億人に達すると予想されています。したがって、高齢化人口の増加は臨床バイオマーカー市場の重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界臨床バイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の臨床バイオマーカー市場：成長率分析
• 世界の臨床バイオマーカー市場の実績：規模と成長, 2019-2024
• 世界の臨床バイオマーカー市場の予測：規模と成長, 2024-2029, 2034F
• 世界臨床バイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の臨床バイオマーカー市場：提供別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 製品
• サービス
• 世界の臨床バイオマーカー市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 次世代シーケンシング（NGS）
• ポリメラーゼ連鎖反応（PCR）
• 免疫組織化学（IHC）
• 酵素免疫測定法（ELISA）
• その他のテクノロジー
• 世界の臨床バイオマーカー市場臨床分野別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がんバイオマーカー
• 心臓バイオマーカー
• 神経学的バイオマーカー
• 感染症バイオマーカー
• 免疫学的バイオマーカー
• 非侵襲的出生前検査
• その他の臨床分野
• 世界の臨床バイオマーカー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床診断
• トランスレーショナル調査
• 世界の臨床バイオマーカー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 契約調査機関（CRO）
• 調査・学術研究所
• バイオ医薬品およびバイオテクノロジー企業
• 診断センター
• その他のエンドユーザー
• 世界の臨床バイオマーカー市場、製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断キット
• 試薬
• アッセイキット
• 機器
• 世界の臨床バイオマーカー市場、サービスの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオマーカー発見サービス
• 分析サービス
• 臨床試験サービス
• データ分析サービス

第7章 地域別・国別分析

• 世界の臨床バイオマーカー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の臨床バイオマーカー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 臨床バイオマーカー市場：競合情勢
• 臨床バイオマーカー市場：企業プロファイル
  • Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck KGaA
• Becton Dickinson and Company
• Eurofins Scientific
• Agilent Technologies Inc.
• Epigenomics AG
• Grifols S.A.
• Illumina Inc.
• BioMerieux SA.
• Charles River Laboratories International Inc.
• PerkinElmer Inc.
• Sartorius AG
• Sysmex Corporation
• Waters Corporation
• Bio-Rad Laboratories Inc.
• Bruker Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 臨床バイオマーカー市場2029：新たな機会を提供する国
• 臨床バイオマーカー市場2029：新たな機会を提供するセグメント
• 臨床バイオマーカー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Clinical biomarkers are quantifiable biological traits that identify normal or diseased bodily functions, encompassing chemicals or physiological indices. They play a crucial role in improving patient care and advancing personalized medicine by providing valuable data about an individual's health condition, disease progression, and potential therapeutic targets.

The main components of clinical biomarkers are products and services. Products in the context of clinical biomarkers are items sold to meet customer needs or desires, whether physical or intangible, and they are utilized to aid in the diagnosis of diseases and conditions. Various technologies are employed in clinical biomarkers, including next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), and others. Clinical biomarkers cover a range of clinical areas, including cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease biomarkers, immunological biomarkers, non-invasive prenatal testing, and others. These biomarkers find applications in clinical diagnostics and translational research and are utilized by various end-users such as contract research organizations (CROs), research and academic laboratories, biopharmaceutical and biotech companies, diagnostic centers, and others.

The clinical biomarkers market research report is one of a series of new reports from The Business Research Company that provides clinical biomarkers market statistics, including clinical biomarkers industry global market size, regional shares, competitors with a clinical biomarkers market share, detailed clinical biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the clinical biomarkers industry. This clinical biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical biomarkers market size has grown strongly in recent years. It will grow from $30.78 billion in 2024 to $33.85 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increased prevalence of chronic disease, focus on personalized medicine and targeted therapies, drug development and clinical trials, regulatory support and funding

The clinical biomarkers market size is expected to see rapid growth in the next few years. It will grow to $52.8 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to expansion of companion diagnostics, focus on early diagnosis and disease prevention, increasing applications in precision oncology and neurodegenerative diseases, growing infectious diseases. Major trends in the forecast period include ai-powered biomarker discovery, machine learning integration, multi-omics integration, technological innovations, key players' partnerships.

The rising prevalence of cancer is expected to drive the growth of the clinical biomarker market in the coming years. Cancer refers to a group of disorders characterized by the uncontrolled growth and division of abnormal cells, which can invade and damage healthy tissues. Clinical biomarkers are essential for cancer prevention as they assist in early detection, risk assessment, and monitoring individuals at heightened risk for developing the disease. For example, Cancer Research UK, a cancer research organization based in the UK, projects an increase in new kidney cancer cases from approximately 16,300 to about 21,900 between 2023 and 2025, representing a 15% rise by 2038-2040. Therefore, the high prevalence of cancer is fueling the growth of the clinical biomarker market.

The expected rise in the aging population is poised to contribute to the growth of the clinical biomarker market. An aging population signifies a demographic shift marked by an increasing proportion of elderly individuals within a society over time. The global aging population is linked to a heightened prevalence of age-related diseases, necessitating biomarkers to enhance early diagnosis and disease management. As of October 2022, the World Health Organization forecasts that by 2030, one out of every six individuals globally will be 60 years old or older. During this period, the population aged 60 and over is projected to rise from 1 billion in 2020 to 1.4 billion. Furthermore, by 2050, the global population of individuals aged 60 and older is expected to double, reaching 2.1 billion. Hence, the increasing aging population is a significant driver of the clinical biomarker market.

Technological advancements emerge as a prominent trend gaining traction in the clinical biomarker market, with major companies focusing on developing innovative technologies to maintain their market positions. For instance, in June 2023, Veravas Inc., a US-based manufacturer of medicinal products for enhancing laboratory medicine, introduced the VeraBIND (Biomarker Isolation and N-enrichment for Detection) technology. This technology offers a uniquely innovative and comprehensive approach to enhance the precision of biomarker identification, reducing the likelihood of false positive or negative results across various sample types. The implementation of VeraBIND in clinical laboratories can improve diagnostic procedures, aiding in early disease detection and enabling prompt, focused interventions. Additionally, VeraBIND facilitates quicker assay creation, ensuring precision and consistency in studies, clinical trials, and diagnostic screenings.

Major companies in the clinical biomarker market are directing their efforts toward developing innovative solutions, including biomarker blood tests. Biomarker blood tests involve assessing specific biomolecules present in the blood to provide information about various physiological or pathological conditions in the body. For instance, in July 2023, Quanterix Corporation, a US-based ultra-sensitive digital immunoassay platform developing company, introduced the 'LucentAD.' This biomarker blood test is designed to assist in assessing patients exhibiting cognitive symptoms consistent with the initial indications of Alzheimer's disease (AD). LucentAD utilizes the extensively researched Simoa p-Tau 181 assay, which has undergone thorough examination in both large longitudinal and cross-sectional cohorts.

In November 2022, Biocare Medical, a global company based in the US, acquired Empire Genomics for an undisclosed amount. This acquisition is aimed at enhancing Biocare Medical's molecular diagnostics portfolio and speeding up the development of cancer biomarkers, ultimately leading to improved patient outcomes through advanced research and diagnostic solutions. This strategic decision bolsters their automation capabilities and positions them as a leader in the cancer diagnostics market. Empire Genomics, also a US-based biotechnology company, specializes in developing genomic tests that identify cancer-related biomarkers, facilitating personalized treatment decisions. These clinical biomarkers assist clinicians in diagnosing, monitoring, and tailoring therapies for improved patient outcomes.

Major companies operating in the clinical biomarkers market include Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., Epigenomics AG, Grifols S.A., Illumina Inc., BioMerieux SA., Charles River Laboratories International Inc., PerkinElmer Inc., Sartorius AG, Sysmex Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Luminex Corporation, Veracyte Inc., Centogene N.V., NanoString Technologies Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Siemens Healthcare Private Limited.

North America was the largest region in the clinical biomakers market in 2024. The regions covered in the clinical biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the clinical biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The clinical biomarkers market consists of revenues earned by entities by providing services such as biomarker assay development, biomarker testing, and biomarker data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The clinical biomarkers market also includes sales of immunoassay kits, point-of-care testing devices, and genetic testing panels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on clinical biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The clinical biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Offering: Product; Service
• 2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Enzyme-Linked Immunosorbent Assay (ELISA); Other Technologies
• 3) By Clinical Area: Cancer Biomarker; Cardiac Biomarker; Neurological Biomarker; Infectious Disease Biomarker; Immunological Biomarker; Non-Invasive Prenatal Testing; Other Clinical Areas
• 4) By Application: Clinical Diagnostic; Translational Research
• 5) By End User: Contract Research Organizations (CROs); Research And Academic Laboratories; Biopharmaceutical And Biotech Companies; Diagnostic Centers; Other End Users
• Subsegments:
• 1) By Product: Diagnostic Kits; Reagents; Assay Kits; Instruments
• 2) By Service: Biomarker Discovery Services; Analytical Services; Clinical Trial Services; Data Analysis Services
• Companies Mentioned: Johnson and Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Clinical Biomarkers Market Characteristics

3. Clinical Biomarkers Market Trends And Strategies

4. Clinical Biomarkers Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Clinical Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Clinical Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Clinical Biomarkers Market Growth Rate Analysis
• 5.4. Global Clinical Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Clinical Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Clinical Biomarkers Total Addressable Market (TAM)

6. Clinical Biomarkers Market Segmentation

• 6.1. Global Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Product
• Service
• 6.2. Global Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Other Technologies
• 6.3. Global Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Biomarker
• Cardiac Biomarker
• Neurological Biomarker
• Infectious Disease Biomarker
• Immunological Biomarker
• Non-Invasive Prenatal Testing
• Other Clinical Areas
• 6.4. Global Clinical Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinical Diagnostic
• Translational Research
• 6.5. Global Clinical Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Contract Research Organizations (CROs)
• Research and Academic Laboratories
• Biopharmaceutical and Biotech Companies
• Diagnostic Centers
• Other End Users
• 6.6. Global Clinical Biomarkers Market, Sub-Segmentation Of Product, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Kits
• Reagents
• Assay Kits
• Instruments
• 6.7. Global Clinical Biomarkers Market, Sub-Segmentation Of Service, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biomarker Discovery Services
• Analytical Services
• Clinical Trial Services
• Data Analysis Services

7. Clinical Biomarkers Market Regional And Country Analysis

• 7.1. Global Clinical Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Clinical Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Clinical Biomarkers Market

• 8.1. Asia-Pacific Clinical Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Clinical Biomarkers Market

• 9.1. China Clinical Biomarkers Market Overview
• 9.2. China Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Clinical Biomarkers Market

• 10.1. India Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Clinical Biomarkers Market

• 11.1. Japan Clinical Biomarkers Market Overview
• 11.2. Japan Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Clinical Biomarkers Market

• 12.1. Australia Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Clinical Biomarkers Market

• 13.1. Indonesia Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Clinical Biomarkers Market

• 14.1. South Korea Clinical Biomarkers Market Overview
• 14.2. South Korea Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Clinical Biomarkers Market

• 15.1. Western Europe Clinical Biomarkers Market Overview
• 15.2. Western Europe Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Clinical Biomarkers Market

• 16.1. UK Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Clinical Biomarkers Market

• 17.1. Germany Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Clinical Biomarkers Market

• 18.1. France Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Clinical Biomarkers Market

• 19.1. Italy Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Clinical Biomarkers Market

• 20.1. Spain Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Clinical Biomarkers Market

• 21.1. Eastern Europe Clinical Biomarkers Market Overview
• 21.2. Eastern Europe Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Clinical Biomarkers Market

• 22.1. Russia Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Clinical Biomarkers Market

• 23.1. North America Clinical Biomarkers Market Overview
• 23.2. North America Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Clinical Biomarkers Market

• 24.1. USA Clinical Biomarkers Market Overview
• 24.2. USA Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Clinical Biomarkers Market

• 25.1. Canada Clinical Biomarkers Market Overview
• 25.2. Canada Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Clinical Biomarkers Market

• 26.1. South America Clinical Biomarkers Market Overview
• 26.2. South America Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Clinical Biomarkers Market

• 27.1. Brazil Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Clinical Biomarkers Market

• 28.1. Middle East Clinical Biomarkers Market Overview
• 28.2. Middle East Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Clinical Biomarkers Market

• 29.1. Africa Clinical Biomarkers Market Overview
• 29.2. Africa Clinical Biomarkers Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Clinical Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Clinical Biomarkers Market, Segmentation By Clinical Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Clinical Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Clinical Biomarkers Market Competitive Landscape
• 30.2. Clinical Biomarkers Market Company Profiles
  • 30.2.1. Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Clinical Biomarkers Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. Becton Dickinson and Company
• 31.3. Eurofins Scientific
• 31.4. Agilent Technologies Inc.
• 31.5. Epigenomics AG
• 31.6. Grifols S.A.
• 31.7. Illumina Inc.
• 31.8. BioMerieux SA.
• 31.9. Charles River Laboratories International Inc.
• 31.10. PerkinElmer Inc.
• 31.11. Sartorius AG
• 31.12. Sysmex Corporation
• 31.13. Waters Corporation
• 31.14. Bio-Rad Laboratories Inc.
• 31.15. Bruker Corporation

32. Global Clinical Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Clinical Biomarkers Market

34. Recent Developments In The Clinical Biomarkers Market

35. Clinical Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Clinical Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Clinical Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Clinical Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer